- Home
- ATAT vs ACAD Comparison
ATAT vs ACAD Comparison
Compare ATAT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAT
- ACAD
- Stock Information
- Founded
- ATAT 2013
- ACAD 1993
- Country
- ATAT China
- ACAD United States
- Employees
- ATAT N/A
- ACAD N/A
- Industry
- ATAT Hotels/Resorts
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- ATAT Consumer Discretionary
- ACAD Health Care
- Exchange
- ATAT Nasdaq
- ACAD Nasdaq
- Market Cap
- ATAT 4.8B
- ACAD 4.3B
- IPO Year
- ATAT 2022
- ACAD 2004
- Fundamental
- Price
- ATAT $39.67
- ACAD $23.61
- Analyst Decision
- ATAT Strong Buy
- ACAD Buy
- Analyst Count
- ATAT 2
- ACAD 21
- Target Price
- ATAT $37.40
- ACAD $29.30
- AVG Volume (30 Days)
- ATAT 1.5M
- ACAD 1.9M
- Earning Date
- ATAT 08-26-2025
- ACAD 11-05-2025
- Dividend Yield
- ATAT 1.13%
- ACAD N/A
- EPS Growth
- ATAT 31.52
- ACAD 615.00
- EPS
- ATAT 1.38
- ACAD 1.33
- Revenue
- ATAT $1,166,553,365.00
- ACAD $1,018,885,000.00
- Revenue This Year
- ATAT $32.05
- ACAD $14.01
- Revenue Next Year
- ATAT $22.51
- ACAD $11.72
- P/E Ratio
- ATAT $28.71
- ACAD $17.81
- Revenue Growth
- ATAT 37.80
- ACAD 14.41
- 52 Week Low
- ATAT $19.54
- ACAD $13.40
- 52 Week High
- ATAT $40.37
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- ATAT 65.18
- ACAD 39.78
- Support Level
- ATAT $38.93
- ACAD $23.70
- Resistance Level
- ATAT $40.24
- ACAD $25.90
- Average True Range (ATR)
- ATAT 1.29
- ACAD 0.74
- MACD
- ATAT 0.15
- ACAD -0.33
- Stochastic Oscillator
- ATAT 87.26
- ACAD 8.16
About ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.